Two Myeloid Leukemia Cases with Rare Fusions

Overview

Journal Cold Spring Harb Mol Case Stud

Specialty Genetics

Date 2018 Dec 19

PMID 30559310

Citations 9

Authors

Haijiao Zhang

Aleksandra Paliga

Evie Hobbs

Stephen Moore

Susan Olson

Nicola Long

Kim-Hien T Dao

Jeffrey W Tyner

Affiliations

Soon will be listed here.

Abstract

Genetic rearrangements involving are rare and only recently have been detected in myeloid/lymphoid neoplasms associated with eosinophilia (MLN-eos) and chronic myeloproliferative disorders. Here we report two cases with fusions in patients demonstrating mixed features of myelodysplastic/myeloproliferative neoplasms. In the first case, was fused with a new fusion partner in a patient with marrow features most consistent with atypical chronic myeloid leukemia; the second case involving - fusion was observed in a case with bone marrow features most consistent with chronic myelomonocytic leukemia. Notably, we observed that samples from both patients demonstrated FLT3 inhibitor (quizartinib and sorafenib) sensitivity in ex vivo drug screening assay.

Citing Articles

Fusion Genes in Myeloid Malignancies.

Ang C, Than H, Tuy T, Goh Y Cancers (Basel). 2024; 16(23).

PMID: 39682241 PMC: 11639841. DOI: 10.3390/cancers16234055.

A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.

Xiao W, Nardi V, Stein E, Hasserjian R J Hematol Oncol. 2024; 17(1):56.

PMID: 39075565 PMC: 11287910. DOI: 10.1186/s13045-024-01571-4.

Clinical and Therapeutic Intervention of Hypereosinophilia in the Era of Molecular Diagnosis.

Nguyen L, Saha A, Kuykendall A, Zhang L Cancers (Basel). 2024; 16(7).

PMID: 38611061 PMC: 11011008. DOI: 10.3390/cancers16071383.

T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.

Schoelinck J, Gervasoni J, Guillermin Y, Beillard E, Pissaloux D, Chassagne-Clement C Virchows Arch. 2023; 484(5):853-857.

PMID: 37985498 DOI: 10.1007/s00428-023-03693-5.

Background and roles: myosin in autoimmune diseases.

Fu L, Zou Y, Yu B, Hong D, Guan T, Hu J Front Cell Dev Biol. 2023; 11:1220672.

PMID: 37691828 PMC: 10484797. DOI: 10.3389/fcell.2023.1220672.

References

Tzankov A, Sotlar K, Muhlematter D, Theocharides A, Went P, Jotterand M . Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol. 2008; 61(8):958-61. DOI: 10.1136/jcp.2008.058073. View

Wandt H, Haferlach T, Thiede C, Ehninger G . WHO classification of myeloid neoplasms and leukemia. Blood. 2010; 115(3):748-9. PMC: 2810993. DOI: 10.1182/blood-2009-10-249664. View

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

Zhang H, Reister Schultz A, Luty S, Rofelty A, Su Y, Means S . Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations. Leukemia. 2017; 31(12):2752-2760. PMC: 5682244. DOI: 10.1038/leu.2017.126. View

Falchi L, Mehrotra M, Newberry K, Lyle L, Lu G, Patel K . ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014; 28(10):2090-2. PMC: 4824944. DOI: 10.1038/leu.2014.168. View

Krause D, Van Etten R . Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353(2):172-87. DOI: 10.1056/NEJMra044389. View

Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N . Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood. 2011; 118(8):2239-42. DOI: 10.1182/blood-2011-03-343426. View

Chung A, Hou Y, Ohgami R, Von Gehr A, Fisk D, Roskin K . A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet. 2017; 216-217:10-15. DOI: 10.1016/j.cancergen.2017.05.001. View

Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A . The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia. 2005; 19(6):1005-9. DOI: 10.1038/sj.leu.2403712. View

10.

Tyner J, Yang W, Bankhead 3rd A, Fan G, Fletcher L, Bryant J . Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2012; 73(1):285-96. PMC: 3537897. DOI: 10.1158/0008-5472.CAN-12-1906. View

11.

Troadec E, Dobbelstein S, Bertrand P, Faumont N, Trimoreau F, Touati M . A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?. Leukemia. 2016; 31(2):514-517. PMC: 5292680. DOI: 10.1038/leu.2016.304. View

12.

Chonabayashi K, Hishizawa M, Matsui M, Kondo T, Ohno T, Ishikawa T . Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia. Ann Hematol. 2013; 93(3):535-7. DOI: 10.1007/s00277-013-1843-9. View

13.

Vu H, Xinh P, Masuda M, Motoji T, Toyoda A, Sakaki Y . FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006; 20(8):1414-21. DOI: 10.1038/sj.leu.2404266. View

14.

Kim D, Salzberg S . TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 2011; 12(8):R72. PMC: 3245612. DOI: 10.1186/gb-2011-12-8-r72. View

15.

Ussowicz M, Jaskowiec A, Meyer C, Marschalek R, Chybicka A, Szczepanski T . A three-way translocation of MLL, MLLT11, and the novel reciprocal partner gene MYO18A in a child with acute myeloid leukemia. Cancer Genet. 2012; 205(5):261-5. DOI: 10.1016/j.cancergen.2012.02.006. View

16.

Sheng G, Zeng Z, Pan J, Kou L, Wang Q, Yao H . Multiple - fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11). Mol Cytogenet. 2017; 10:4. PMC: 5329908. DOI: 10.1186/s13039-017-0306-8. View

17.

Grand F, Iqbal S, Zhang L, Russell N, Chase A, Cross N . A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol. 2007; 35(11):1723-7. DOI: 10.1016/j.exphem.2007.07.002. View